No abstract

Onychomycosis is a common chronic fungal infection of the nails caused by dermatophytes, yeasts, and non-dermatophyte filamentous fungi. A relatively high incidence of resistance and treatment failure of onychomycosis to traditional systemic antifungal agents such as terbinafine and itraconazole has been reported. Voriconazole is a novel broad spectrum systemic antifungal that has shown high efficacy against various types of dermatophytes including Trichophyton and Microsporum species in many in vitro and, recently, in two in vivo studies of resistant dermatophytosis. Ahmad Nofal and Mohamed M. Fawzy belong to the Member of Interactive Dermatology Research Group.

Background and Objectives To compare the efficacy of autologous platelet‐rich plasma (PRP), ablative fractional carbon dioxide (FCO2) laser, and their combination in the treatment of atrophic acne scars, both clinically and immuno‐histopathologically. Study Design/Materials and Methods Sixty patients were randomly divided into three equal groups. Group 1 received intradermal PRP injection sessions. Group 2 received FCO2 laser sessions. Group 3 received FCO2 laser followed by intradermal PRP injection sessions. Each group received three sessions at monthly intervals. The final assessment took place 3 months after the last session. Skin biopsies were obtained before and 1 month after treatment sessions with pathological evaluation. Results Combined PRP and FCO2 laser‐treated patients had a better clinical response, fewer side effects, and shorter downtime than FCO2 laser alone. PRP‐treated patients had some improvement but significantly lower than the other two groups. Conclusion The current study concluded that a combination of PRP and FCO2 laser is an effective and safe modality in the treatment of atrophic acne scars with better results than PRP or FCO2 laser alone. Lasers Surg. Med. © 2020 Wiley Periodicals LLC

Long pulse Nd-YAG laser therapy of onychomycosis is a safe and efficient method for treating onychomycosis. It is especially beneficial in elderly, compromised and hepatopathic patients for whom other alternative treatments could present some risks.

The clinical presentation of severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2 COVID‐19) varies from asymptomatic infection to a life‐threatening, multiorgan disease. One of these manifestations is telogen effluvium (TE) which is characterized by diffuse hair loss occurring in patients previously infected with SARS‐CoV‐2 and lasts ~3 months, after which excessive hair loss follows. Hair follicles are known to contain a well‐characterized niche for adult stem cells which is the bulge containing epithelial and melanocytic stem cells. Stem cells in the hair bulge, a demarcated structure within the lower permanent portion of hair follicles, can generate the interfollicular epidermis, hair follicle structures, and sebaceous glands. This study aims to evaluate autologous micrografts from scalp tissues as a therapeutic modality in the management of TE caused by COVID‐19. Twenty patients of previous COVID‐19 infection suffered from TE were included in this study for human follicle stem cells micrograft scalp treatment and they were evaluated after 3 months of treatment and after 6 months. There was significant improvement of the hair thickness and density compared with the start of the treatment and 6 months of follow‐up. Autologous micrograft of the scalp showed marked improvement in the treatment of COVID‐19 TE.